Liraglutide
An earlier, shorter-acting GLP-1 receptor agonist taken daily, sold for weight management as Saxenda.
Liraglutide is a first-generation GLP-1 receptor agonist that requires a daily injection, unlike the newer once-weekly drugs. As Saxenda it is approved for weight management, producing average loss in the high single digits percent of body weight, less than semaglutide or tirzepatide. In the regain meta-analysis, liraglutide showed the smallest absolute rebound after stopping, largely because its on-treatment loss is smaller.